
zzso studies show that zzso zzso and zzso zzso zzso are synergistic against MA zzso zzso zzso Both agents are highly active as zzso in a number of tumors, including zzso breast zzso zzso we performed a phase I zzso study to determine the maximum tolerated dose of this combination regimen in patients with advanced solid zzso A total of 45 patients were enrolled and received zzso followed by zzso both administered as zzso intravenous infusions once every 3 zzso The dose levels of zzso were zzso zzso zzso zzso zzso zzso zzso zzso zzso zzso zzso zzso zzso zzso zzso zzso zzso zzso zzso zzso zzso zzso zzso zzso and zzso zzso zzso zzso Patients with zzso zzso in groups 5 and 6 received 300 zzso of zzso zzso factor zzso zzso zzso support on days 2 through 9 during subsequent cycles of zzso All patients received zzso with 8 zzso of zzso twice daily for 5 days, beginning 1 day prior to zzso The zzso toxicity was zzso zzso The recommended dose for phase II studies of zzso is zzso zzso in previously treated patients and zzso zzso in previously zzso zzso zzso support did not allow for further dose zzso zzso results from this phase I trial indicate that the combination of zzso and zzso produced an objective response rate of zzso in 32 patients with zzso breast cancer (including 3 patients who achieved complete zzso 

